Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.530

+7.5%

Dec 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (1)	4/6/2000 9:06:00 PM
From: Mike McFarland	Read Replies (2) of 368

Drug Discovery 2000 Wednesday April 12, 2000 Engineering Transcription Factors to Selectively Control Gene Expression The C2-H2 class of zinc finger DNA binding domains has provided a structural basis for the design and assembly of DNA binding proteins with novel sequence specificities. Methods for high-throughput assembly and biochemical characterization of these novel proteins has led to a better understanding of their binding properties. Using reiterative design processes, proteins having singular site specificity over a range of 18 basepairs have been produced. By combining these targeting proteins with transcriptional activation and repression domains, gene specific transcription factors have been made. These transcription factors have the ability to both up- and down-regulate the expression of the gene to which they are targeted. The technology is being applied in cellular and animal models for the determination of gene function and validation of gene targets for pharmaceutical drug development Edward Rebar, Ph.D., Scientist, Sangamo Biosciences Inc. drugdiscovery2000.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next